• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.

作者信息

Vilsbøll Tina, Zdravkovic Milan, Le-Thi Tu, Krarup Thure, Schmitz Ole, Courrèges Jean-Pierre, Verhoeven Robert, Bugánová Ingrid, Madsbad Sten

机构信息

Department of Internal Medicine, Gentofte Hospital, Hellerup, Denmark.

出版信息

Diabetes Care. 2007 Jun;30(6):1608-10. doi: 10.2337/dc06-2593. Epub 2007 Mar 19.

DOI:10.2337/dc06-2593
PMID:17372153
Abstract
摘要

相似文献

1
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.利拉鲁肽是一种长效人胰高血糖素样肽-1类似物，作为单一疗法给药时，可显著改善2型糖尿病患者的血糖控制并降低体重，且无低血糖风险。
Diabetes Care. 2007 Jun;30(6):1608-10. doi: 10.2337/dc06-2593. Epub 2007 Mar 19.
2
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).人胰高血糖素样肽-1类似物利拉鲁肽联合二甲双胍和噻唑烷二酮治疗2型糖尿病患者的疗效和安全性（LEAD-4 Met+TZD研究）
Diabetes Care. 2009 Jul;32(7):1224-30. doi: 10.2337/dc08-2124. Epub 2009 Mar 16.
3
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.长效胰高血糖素样肽-1类似物利拉鲁肽（NN2211）每日一次治疗2型糖尿病患者可改善血糖控制且不增加体重：一项为期12周的双盲、随机、对照试验。
Diabetes Care. 2004 Jun;27(6):1335-42. doi: 10.2337/diacare.27.6.1335.
4
[New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose].[来自美国糖尿病大会的新数据。胰高血糖素样肽-1的作用：不止于降低血糖]
MMW Fortschr Med. 2010 Oct 7;152(40):44-5.
5
Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy.德谷胰岛素/利拉鲁肽：推动糖尿病治疗进展的创新组合。
Expert Opin Biol Ther. 2014 Jun;14(6):869-78. doi: 10.1517/14712598.2014.904851. Epub 2014 Apr 5.
6
[Liraglutide: new results in the treatment of type 2 diabetes mellitus].[利拉鲁肽：2型糖尿病治疗的新成果]
Drugs Today (Barc). 2012 Jul;48 Suppl B:1-17. doi: 10.1358/dot.2012.48(Suppl.B).1876681.
7
Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.利拉鲁肽，一种胰高血糖素样肽-1（GLP-1）类似物，对日本肥胖 2 型糖尿病患者的体重、饮食行为和血糖控制的疗效。
Cardiovasc Diabetol. 2012 Sep 14;11:107. doi: 10.1186/1475-2840-11-107.
8
Liraglutide for the treatment of type 2 diabetes: a clinical update.利拉鲁肽治疗 2 型糖尿病：临床更新。
Am J Ther. 2013 Mar-Apr;20(2):178-88. doi: 10.1097/MJT.0b013e3182204c16.
9
Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.每日一次利拉鲁肽可使血糖呈剂量依赖性改善，且无低血糖或体重增加：一项针对日本2型糖尿病患者的双盲、随机、对照试验。
Diabetes Res Clin Pract. 2008 Aug;81(2):161-8. doi: 10.1016/j.diabres.2008.03.018. Epub 2008 May 20.
10
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.利拉鲁肽、格列美脲与安慰剂联合二甲双胍治疗 2 型糖尿病的长期疗效和安全性比较：LEAD-2 研究 2 年结果。
Diabetes Obes Metab. 2013 Mar;15(3):204-12. doi: 10.1111/dom.12012. Epub 2012 Oct 11.

引用本文的文献

1
How multispecific molecules are transforming pharmacotherapy.多特异性分子如何改变药物治疗。
Nat Rev Drug Discov. 2025 Aug 1. doi: 10.1038/s41573-025-01262-w.
2
Glucose-dependent insulinotropic polypeptide (GIP).葡萄糖依赖性促胰岛素多肽（GIP）。
Mol Metab. 2025 May;95:102118. doi: 10.1016/j.molmet.2025.102118. Epub 2025 Feb 28.
3
Effects of liraglutide on abdominal fat distribution and glucose metabolism in Chinese subjects with obesity.利拉鲁肽对中国肥胖受试者腹部脂肪分布及糖代谢的影响。
Diabetol Metab Syndr. 2024 Dec 20;16(1):307. doi: 10.1186/s13098-024-01540-4.
4
Hepatic function of glucagon-like peptide-1 and its based diabetes drugs.胰高血糖素样肽-1及其基础糖尿病药物的肝功能
Med Rev (2021). 2024 Jun 4;4(4):312-325. doi: 10.1515/mr-2024-0018. eCollection 2024 Aug.
5
From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists.从糖尿病到多个领域：GLP-1 受体激动剂的多面角色。
Mol Biol Rep. 2024 Jul 23;51(1):835. doi: 10.1007/s11033-024-09793-y.
6
Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity.司美格鲁肽和利拉鲁肽作为肥胖治疗选择的分子机制
Front Nutr. 2024 Apr 29;11:1398059. doi: 10.3389/fnut.2024.1398059. eCollection 2024.
7
Treat Obesity to Treat Type 2 Diabetes Mellitus.治疗肥胖以治疗2型糖尿病。
Diabetes Ther. 2024 Mar;15(3):611-622. doi: 10.1007/s13300-024-01536-3. Epub 2024 Feb 4.
8
The Effect of Liraglutide on Axon Regeneration and Functional Recovery after Peripheral Nerve Lesion.利拉鲁肽对周围神经损伤后轴突再生和功能恢复的影响。
Curr Issues Mol Biol. 2024 Jan 2;46(1):327-339. doi: 10.3390/cimb46010021.
9
Testing a new platform to screen disease-modifying therapy in type 1 diabetes.测试一种新的平台，以筛选 1 型糖尿病的疾病修正疗法。
PLoS One. 2023 Dec 14;18(12):e0293268. doi: 10.1371/journal.pone.0293268. eCollection 2023.
10
Efficacy and Safety of a Biosimilar Liraglutide (Melitide) Versus the Reference Liraglutide (Victoza) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial.一种生物类似物利拉鲁肽（Melitide）与参比利拉鲁肽（Victoza）在2型糖尿病患者中的疗效和安全性：一项随机、双盲、非劣效性临床试验
Diabetes Ther. 2023 Nov;14(11):1889-1902. doi: 10.1007/s13300-023-01462-w. Epub 2023 Sep 14.